Comparative cardiac toxicity in two treatment schedules of 5-FU/LV for colorectal carcinoma

被引:0
|
作者
Najam, Rahila [1 ]
Bano, Nusrat [1 ]
Mateen, Ahmed [2 ]
机构
[1] Univ Karachi, Fac Pharm, Dept Pharmacol, Karachi, Pakistan
[2] KIRAN, Karachi, Pakistan
关键词
Colorectal Carcinoma; Cardiac Toxicity; 5-FU; CPK; GOT; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR COMPLICATIONS; CANCER-THERAPY; 5-FLUOROURACIL; CARDIOTOXICITY; PATHOGENESIS; DIAGNOSIS; INFUSION; PATIENT;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The purpose of the study is evaluation and assessment of parameters of cardiac toxicity in patients subjected to 5-FU based chemotherapy. Cardiac morbidity is a reported outcome in different 5FU/LV regimens; however none of them are definite or proximate. The bimonthly regimen of high dose leucovorin is reported to be less toxic and more effective as compared to the monthly regimen of low dose leucovorin. We report the detailed assessment of few cardiac parameter of toxicity in patients of advanced colorectal carcinoma subjected to two Schedules of high and low dose Folinic Acid, 5-Fluorouracil, bolus and continuous infusion. The correlation of elevated cardiac biomarkers, angina and hypertension is comparatively assessed in patients with normal general status, hyperglycemia and known cardiac disorders subjected to two different 5FU based chemotherapeutic regimen.
引用
收藏
页码:1013 / 1022
页数:10
相关论文
共 50 条
  • [21] Trimetrexate (TMTX) modulation of 5-fluorouracil leucovorin (5-FU/LV) for advanced colorectal cancer
    Blanke, C
    Kasimis, B
    Schein, P
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 748 - 748
  • [22] A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer
    M. G. Fakih
    A. Groman
    J. McMahon
    G. Wilding
    J. R. Muindi
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 743 - 751
  • [23] Beyond 5-FU - Future approaches for the treatment of colorectal cancer
    Haller, DG
    ONKOLOGIE, 2000, 23 : 5 - 8
  • [24] SEQUENTIAL METHOTREXATE AND 5-FU IN THE TREATMENT OF COLORECTAL-CANCER
    WEINERMAN, B
    SCHACTER, B
    SCHIPPER, H
    BOWMAN, D
    LEVITT, M
    CANCER TREATMENT REPORTS, 1982, 66 (07): : 1553 - 1555
  • [25] 5-FU TOXICITY AND NUTRITIONAL DEFICIENCIES
    STENRAM, U
    BRITISH JOURNAL OF CANCER, 1993, 67 (05) : 1157 - 1157
  • [26] First-line Treatment of Advanced Biliary Ducts Carcinoma: A Randomized Phase II Study Evaluating 5-FU/LV Plus Oxaliplatin (Folfox 4) Versus 5-FU/LV (de Gramont Regimen)
    Schinzari, Giovanni
    Rossi, Ernesto
    Mambella, Giuseppina
    Strippoli, Antonia
    Cangiano, Rodolfo
    Mutignani, Massimiliano
    Basso, Michele
    Cassano, Alessandra
    Barone, Carlo
    ANTICANCER RESEARCH, 2017, 37 (09) : 5193 - 5197
  • [27] Colorectal cancer - Is there an alternative to 5-FU?
    Bleiberg, H
    EUROPEAN JOURNAL OF CANCER, 1997, 33 (04) : 536 - 541
  • [28] COMBINATION CHEMOTHERAPY OF CISPLATIN AND 5-FU IN ADVANCED COLORECTAL-CARCINOMA
    DY, C
    GIL, A
    ALGARRA, SM
    APARICIO, LA
    CALVO, F
    HERRANZ, P
    CANCER TREATMENT REPORTS, 1986, 70 (04): : 465 - 468
  • [29] Compliance and toxicity in metastatic colorectal carcinoma patients treated with capecitabine versus 5-FU associated with oxaliplatin or irinotecan
    Raimondi, C.
    Longo, F.
    Tomao, S.
    Ricciardi, S.
    Rosati, S.
    Messina, C. G. M.
    Cerbone, L.
    Spalletta, B.
    Russillo, M.
    Di Seri, M.
    ANNALS OF ONCOLOGY, 2006, 17 : XI43 - XI43
  • [30] CLINICAL SIGNIFICANCE FOR '5-FU CHEMOSENSITIVITY' OF IN-VITRO MTT ASSAY IN 5-FU/LV ADJUVANT CHEMOTHERAPY AFTER CURATIVE RESECTION OF COLORECTAL CANCER.
    Um, J.
    Ryu, J.
    Han, K.
    Min, B.
    Lee, J.
    Kim, Y.
    DISEASES OF THE COLON & RECTUM, 2011, 54 (05) : E125 - E126